Loading organizations...
Loading organizations...
BioVidria: Biotechnology company developing materials for protein analysis and rapid disease detection, advancing pharmaceuticals and patient health.
BioVidria is a biotechnology company that develops advanced materials and technological products designed for rapid protein analysis and disease detection. The organization's solutions aim to accelerate diagnostic testing and biological research processes across the pharmaceutical, proteomics, and agriculture sectors. Specifically, the proprietary technology identifies critical drug impurities to aid in the development of treatments for patients with cancer and severe autoimmune conditions, such as Type I diabetes, multiple sclerosis, Crohn's disease, and lupus. To scale its research and development efforts, BioVidria has secured financial backing from notable institutions, including an initial $75,000 investment from the Emerging Innovations Fund at Purdue University and a subsequent $1 million grant from the National Institutes of Health. The enterprise was established by founder Mary J. Wirth, who serves as the W. Brooks Fortune Distinguished Professor of Chemistry at Purdue University.
BioVidria has raised $75K across 1 funding round.
BioVidria has raised $75K in total across 1 funding round.
BioVidria has raised $75K in total across 1 funding round.
BioVidria's investors include Elizabeth Hart-Wells.
BioVidria has raised $75K across 1 funding round. Most recently, it raised $75K Seed in February 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 13, 2014 | $75K Seed | Elizabeth Hart-Wells |